title: Heparin-mediated extracorporeal low-density lipoprotein precipitation: rationale for a specific adjuvant therapy in cardiovascular disease.
abstract: Various radical measures for the treatment of severe hypercholesterolemia such as partial ileal bypass, portocaval shunt, liver transplantation and plasma exchange have been tested in patients in whom drug and diet failed or were insufficient. Although effective, most of these treatments have severe side effects and are not routinely used. For hypercholesterolemic patients LDL-apheresis has proved to be the most promising and safe way as an adjuvant therapy. Several LDL-apheresis procedures with a varying degree of selectivity and efficiency have subsequently been developed. One of them is the H.E.L.P. system which was introduced in 1984 and has now been widely used. Besides the marked reduction of LDL particles by all techniques it has become apparent that only the H.E.L.P. system results in an equally significant change in hemostaseology, hemorheology and vasomotion because of its simultaneously removal of LDL, Lp(a), fibrinogen and CRP. This contribution reviews the application of the H.E.L.P. system as a valuable therapeutic tool for the treatment of various atherothrombotic and microcirculatory disorders such as prevention of early graft occlusion after coronary artery bypass grafting, treatment of peripheral vascular disease, stroke and preeclampsia.
authors.affiliation: Institut für Klinische Chemie, Ludwig-Maximilians-Universität München (Klinikum Grosshadern), Marchioninistr. 15, D-81377 München, Germany. frithjof.blessing@klch.med.uni-muenchen.de
authors.forename: Frithjof
authors.initials: F
authors.lastname: Blessing
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Autar K
authors.initials: AK
authors.lastname: Walli
authors.forename: Dietrich
authors.initials: D
authors.lastname: Seidel
mesh_terms: D000328:Adult; D001781:Blood Component Removal / Q000379:methods*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000628:therapy*; D002648:Child; D000529:Complementary Therapies / Q000379:methods*; D005112:Extracorporeal Circulation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000628:therapy; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D016896:Treatment Outcome
chemical_list: D008077:Lipoproteins, LDL; D006493:Heparin